Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009-2014.

Tsai HC, Chen IT, Wu KS, Tseng YT, Sy CL, Chen JK, Lee SS, Chen YS.

Infect Drug Resist. 2017 Oct 16;10:343-352. doi: 10.2147/IDR.S146584. eCollection 2017.

2.

Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada.

Rocheleau G, Franco-Villalobos C, Oliveira N, Brumme ZL, Rusch M, Shoveller J, Brumme CJ, Harrigan PR.

PLoS One. 2017 Sep 22;12(9):e0184848. doi: 10.1371/journal.pone.0184848. eCollection 2017.

3.

Survival benefits of antiretroviral therapy in Brazil: a model-based analysis.

Luz PM, Girouard MP, Grinsztejn B, Freedberg KA, Veloso VG, Losina E, Struchiner CJ, MacLean RL, Parker RA, Paltiel AD, Walensky RP.

J Int AIDS Soc. 2016 Mar 29;19(1):20623. doi: 10.7448/IAS.19.1.20623. eCollection 2016.

4.

HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument.

Lapointe HR, Dong W, Lee GQ, Bangsberg DR, Martin JN, Mocello AR, Boum Y, Karakas A, Kirkby D, Poon AF, Harrigan PR, Brumme CJ.

Antimicrob Agents Chemother. 2015 Nov;59(11):6824-33. doi: 10.1128/AAC.01490-15. Epub 2015 Aug 17.

5.

Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections.

Tang YW, Ou CY.

Emerg Microbes Infect. 2012 Aug;1(8):e19. doi: 10.1038/emi.2012.15. Epub 2012 Aug 22. Review.

6.

Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysis.

Wolf T, Fuß B, Khaykin P, Berger A, Knecht G, Gute P, Brodt HR, Goepel S, Bickel M, Stuermer M, Stephan C; Frankfurt HIV Cohort Study.

Med Microbiol Immunol. 2014 Dec;203(6):409-14. doi: 10.1007/s00430-014-0350-5. Epub 2014 Aug 23.

7.

Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa.

McCormick AW, Abuelezam NN, Rhode ER, Hou T, Walensky RP, Pei PP, Becker JE, DiLorenzo MA, Losina E, Freedberg KA, Lipsitch M, Seage GR 3rd.

PLoS One. 2014 May 27;9(5):e98272. doi: 10.1371/journal.pone.0098272. eCollection 2014.

8.

Dynamics analysis and simulation of a modified HIV infection model with a saturated infection rate.

Sun Q, Min L.

Comput Math Methods Med. 2014;2014:145162. doi: 10.1155/2014/145162. Epub 2014 Mar 23.

9.

HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure.

Swenson LC, Min JE, Woods CK, Cai E, Li JZ, Montaner JS, Harrigan PR, Gonzalez-Serna A.

AIDS. 2014 May 15;28(8):1125-34. doi: 10.1097/QAD.0000000000000203.

10.
11.

Comparing Peripheral Blood Mononuclear Cell DNA and Circulating Plasma viral RNA pol Genotypes of Subtype C HIV-1.

Banks L, Gholamin S, White E, Zijenah L, Katzenstein DA.

J AIDS Clin Res. 2012 Feb;3(2):141-147.

12.

Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.

Rath BA, Olshen RA, Halpern J, Merigan TC.

Viruses. 2012 Aug;4(8):1212-34. doi: 10.3390/v4081212. Epub 2012 Aug 7.

13.

Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool.

Woods CK, Brumme CJ, Liu TF, Chui CK, Chu AL, Wynhoven B, Hall TA, Trevino C, Shafer RW, Harrigan PR.

J Clin Microbiol. 2012 Jun;50(6):1936-42. doi: 10.1128/JCM.06689-11. Epub 2012 Mar 7.

14.

A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Shafer RW, Dupnik K, Winters MA, Eshleman SH.

HIV Seq Compend. 2001;2001:1-51. No abstract available.

15.

Clinical management of HIV drug resistance.

Cortez KJ, Maldarelli F.

Viruses. 2011 Apr;3(4):347-78. doi: 10.3390/v3040347. Epub 2011 Apr 14. Review.

16.

Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays.

Emmadi R, Boonyaratanakornkit JB, Selvarangan R, Shyamala V, Zimmer BL, Williams L, Bryant B, Schutzbank T, Schoonmaker MM, Amos Wilson JA, Hall L, Pancholi P, Bernard K.

J Mol Diagn. 2011 Nov;13(6):583-604. doi: 10.1016/j.jmoldx.2011.05.011. Epub 2011 Aug 25. Review.

17.

The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention.

Hong SY, Nachega JB, Kelley K, Bertagnolio S, Marconi VC, Jordan MR.

Infect Disord Drug Targets. 2011 Apr;11(2):124-33. Review.

18.

"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice.

Swenson LC, Pollock G, Wynhoven B, Mo T, Dong W, Hogg RS, Montaner JS, Harrigan PR.

PLoS One. 2011 Feb 24;6(2):e17402. doi: 10.1371/journal.pone.0017402.

19.

Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study.

Fehr J, Glass TR, Louvel S, Hamy F, Hirsch HH, von Wyl V, Böni J, Yerly S, Bürgisser P, Cavassini M, Fux CA, Hirschel B, Vernazza P, Martinetti G, Bernasconi E, Günthard HF, Battegay M, Bucher HC, Klimkait T; Swiss HIV Cohort Study.

J Transl Med. 2011 Jan 21;9:14. doi: 10.1186/1479-5876-9-14.

20.

Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models.

Prosperi MC, Rosen-Zvi M, Altmann A, Zazzi M, Di Giambenedetto S, Kaiser R, Schülter E, Struck D, Sloot P, van de Vijver DA, Vandamme AM, Sönnerborg A; EuResist study group; Virolab study group.

PLoS One. 2010 Oct 29;5(10):e13753. doi: 10.1371/journal.pone.0013753. Erratum in: PLoS One. 2011;6(4). doi:10.1371/annotation/d0254103-21b9-4078-836b-57ba5bd1c26a.

Supplemental Content

Support Center